Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postpartum Aortic Dissection Without Aortic Dilation in a Woman With an ACTA2 Gene Mutation.

JACC. Case reports·2026
Same author

Long-term real-world effectiveness and safety of edoxaban in chronic thromboembolic pulmonary hypertension: a nationwide registry study.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Defecation Patterns and Cardiovascular Outcomes in Acute Coronary Syndrome: The Influence of Stimulant Laxative Use.

JACC. Asia·2026
Same author

Right Atrial Function as a Novel Predictor for New-Onset Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy.

Journal of the American Heart Association·2026
Same author

Epidemiological and clinical evidence on blood pressure management for the prevention of dementia: striving for a healthy 100-year life.

Hypertension research : official journal of the Japanese Society of Hypertension·2026
Same author

High Human Epididymis Protein 4 Levels Are Associated With Lower Systolic Function and Poor Prognosis in Heart Failure With Reduced Ejection Fraction.

Circulation journal : official journal of the Japanese Circulation Society·2026
Same journal

Discontinuation of Oral Anticoagulation After Successful Catheter Ablation for Atrial Fibrillation: Meta-analysis of Randomized Clinical Trials.

Thrombosis and haemostasis·2026
Same journal

Novel/Recurrent Variants in Pakistani Glanzmann Thrombasthenia and Glanzmann-like bleeding diathesis: Insights from NGS Analysis.

Thrombosis and haemostasis·2026
Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026
Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026
Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026
Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026
See all related articles

Related Experiment Video

Updated: Jan 10, 2026

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

7.2K

Profiling Initial Thrombin Generation in Cardiovascular Disease Using a High Sensitivity Coagulation Assay.

Akira Fujiyama1,2, Yuichiro Arima1,3,4, Rina Inoue5

  • 1Developmental Cardiology Laboratory, International Research Center for Medical Science (IRCMS), Kumamoto University, Kumamoto, Japan.

Thrombosis and Haemostasis
|November 21, 2025
PubMed
Summary
This summary is machine-generated.

Initial thrombin generation (ITG) measurement shows promise for monitoring anticoagulant therapy. Different pathways of ITG are affected by direct oral anticoagulants and various diseases, offering insights into coagulation potential.

More Related Videos

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis
03:53

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

1.2K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.3K

Related Experiment Videos

Last Updated: Jan 10, 2026

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

7.2K
Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis
03:53

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

1.2K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.3K

Area of Science:

  • Coagulation science
  • Biomarker discovery
  • Thrombosis research

Background:

  • Initial thrombin generation (ITG) is crucial for blood coagulation, initiated by tissue factor (TF)-driven and FVIIIa/FIXa-dependent pathways.
  • The clinical utility of ITG as a thrombogenicity marker or for monitoring oral anti-FXa therapy is not well-established.

Purpose of the Study:

  • To assess the clinical utility of measuring ITG via TF-driven and FVIIIa/FIXa-dependent pathways.
  • To evaluate the impact of direct oral anticoagulants (DOACs) and clinical conditions on ITG.
  • To determine if ITG can serve as a biomarker for anticoagulant efficacy.

Main Methods:

  • ITG was measured in plasma from healthy adults and 771 cardiovascular disease patients.
  • Analysis included patients on DOACs and those not on anticoagulants.
  • Receiver operating characteristic (ROC) analysis and logistic regression were used to evaluate ITG pathways.

Main Results:

  • DOAC treatment significantly suppressed thrombin generation in both TF-driven and FVIIIa/FIXa-dependent pathways.
  • ROC analysis showed high discriminatory power for both pathways in detecting DOAC use.
  • Dialysis, chronic kidney disease, and active cancer were associated with altered ITG, with specific impacts on the TF-driven pathway.

Conclusions:

  • ITG potentials from TF- and FVIIIa/FIXa-dependent pathways are promising biomarkers for assessing anticoagulant efficacy.
  • Distinct pathological conditions differentially affect coagulation pathways, necessitating consideration of disease context in ITG assessment.